title: Use of novel oral anticoagulant agents in venous thromboembolism.
abstract: New oral anticoagulants (NOAC) serve as alternatives for patients currently using warfarin for the prevention and treatment of venous thromboembolic (VTE) disease. This article provides a brief summary of the clinical use of these drugs as well as a review of the landmark clinical trials which evaluated described their safety and efficacy. As more data becomes available, a fundamental understanding of these medications will be vital to cardiovascular practitioners managing patients with VTE.
authors.affiliation: Department of Cardiovascular Medicine, University of North Carolina Hospitals, Chapel Hill, NC, USA.
authors.forename: Shivanshu
authors.initials: S
authors.lastname: Madan
authors.affiliation: Department of Cardiovascular Medicine, University of Wisconsin, Madison, WI, USA.
authors.forename: Shenil
authors.initials: S
authors.lastname: Shah
authors.affiliation: Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, NC, USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Dale
authors.affiliation: Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
authors.forename: Sasan
authors.initials: S
authors.lastname: Partovi
authors.affiliation: Center for Interventional Vascular Therapy and Division of Cardiology, Department of Medicine, Columbia University Medical Center and Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Sahil A
authors.initials: SA
authors.lastname: Parikh
keywords: Warfarin; apixaban; dabigatran; deep vein; edoxaban; pulmonary embolism (PE); rivaroxaban; thrombosis